Clinical trials
Urothelial Carcinoma clinical trials
Below are recruiting urothelial carcinoma clinical trials, each written for real people, not researchers. We’re tracking 203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04628767RecruitingPhase 2/Phase 3
Durvalumab plus chemo before surgery for upper tract cancer
This trial tests whether adding an immunotherapy drug (durvalumab) to chemotherapy before surgery can improve outcomes for people with high-grade upper tract urothelial cancer. It compares different treatment approaches based on whether a patient can receive cisplatin chemotherapy.
Kingman, ArizonaAges 18 years+ - NCT05912816RecruitingPhase 2
Kidney-protecting treatment for high-risk upper urinary tract cancer
This trial tests whether combining DV with tislelizumab can help protect kidney function in people with high-risk cancer in the upper urinary tract (the renal pelvis or ureter). It may help preserve the kidneys while treating the cancer more effectively.
Shanghai, Shanghai MunicipalityAges 18–90 - NCT06169436Recruiting
Study of People with Upper Tract Urothelial Cancer Having Surgery
This study watches people with upper tract urothelial cancer who are having surgery to remove the kidney and ureter. It aims to collect information to better understand the disease and improve future care.
Milan, MIAges 18 years+ - NCT07225374RecruitingPhase 2
Avelumab after chemotherapy for upper tract urothelial cancer
This trial is for people with upper tract urothelial cancer who have already had surgery and chemotherapy (cisplatin-based). It tests whether continuing with a drug called avelumab (an immunotherapy) can help prevent the cancer from coming back.
Seoul, GangnamAges 20 years+ - NCT07728474Recruiting
Herbal supplement to prevent bladder cancer recurrence
This trial tests a herbal formula called LCS103 to see if it can help prevent bladder cancer from coming back after a tumor has been removed. It is for people with non-invasive bladder cancer that has been fully taken out by surgery.
HaifaAges 18 years+ - NCT07061964RecruitingPhase 2
Immunotherapy and radiation to save the bladder
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Birmingham, AlabamaAges 18 years+ - NCT07726602Recruiting
Tumor DNA blood test for muscle-invasive bladder cancer
This trial uses a blood test to look for small pieces of tumor DNA (ctDNA) after treatment for muscle-invasive bladder cancer. It aims to find out if the test can detect leftover or returning cancer earlier, helping guide next steps.
Portland, OregonAges 18 years+ - NCT07518043RecruitingPhase 1
HLX18 vs. Opdivo after surgery for solid tumors
This trial compares two immune-boosting drugs (HLX18 and Opdivo, also called nivolumab) in patients who have had surgery to remove certain cancers—including esophageal, melanoma, or bladder cancer—with no signs of cancer remaining. The goal is to see which drug helps prevent the cancer from coming back.
FuzhouAges 18–70 - NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
Grand Rapids, MichiganAges 18 years+ - NCT07720284RecruitingPhase 3
Testing new drugs for high-risk bladder cancer after surgery
This trial tests a new combination of drugs (Dato-DXd plus rilvegostomig) against standard treatments for people with high-risk, muscle-invasive bladder cancer that has been surgically removed. The goal is to see if the new treatment reduces the chance of the cancer coming back.
Hot Springs, ArkansasAges 18 years+ - NCT07717242RecruitingPhase 2
Bladder cancer study testing a new drug combination before surgery
This trial is testing a combination of two drugs (disitamab vedotin and toripalimab) for people with muscle-invasive bladder cancer that has not spread. The goal is to see if this treatment can shrink the tumor before surgery. You may qualify if your tumor has a certain level of a protein called HER2.
Guangzhou, GuangdongAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT03185468RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced bladder cancer
This Phase 1/2 trial tests CAR-T therapy—a treatment where immune cells are changed to better attack cancer—for bladder cancer that has spread or grown locally. It may help shrink tumors and control the disease by boosting a patient’s immune response.
Shenzhen, GuangdongAges 18–65 - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04574960RecruitingPhase 3
Neoadjuvant chemotherapy before kidney/ureter cancer surgery
This Phase 3 trial studies giving cisplatin-based chemotherapy before surgery for certain newly diagnosed upper-urinary-tract urothelial cancers (kidney/ureter). It may help shrink the cancer and improve outcomes by treating microscopic disease earlier.
Ottawa, OntarioAges 18 years+ - NCT04588168Recruiting
MRI helps guide bladder cancer treatment planning
This trial uses special MRI scans to help doctors choose precise treatment for bladder cancer before and/or around surgery. It may help tailor therapy more accurately while you receive standard bladder cancer care.
Nanjing, JiangsuAges 18 years+ - NCT04641936Recruiting
Urine tests to predict response to immunotherapy in bladder cancer
This study uses urine “omics” tests (detailed lab patterns from urine) to predict whether immunotherapy will work for people with metastatic urothelial (bladder/urinary tract) cancer. It may help doctors choose the right treatment sooner by identifying who is more likely to benefit.
TaipeiAges 20 years+ - NCT04977453RecruitingPhase 1/Phase 2
Study drug GI-101 alone or with immune or blood-pressure meds
This early-phase study tests GI-101 in people with advanced solid cancers. It may be given alone or combined with pembrolizumab or lenvatinib to see how safe it is and whether it can shrink tumors.
New York, New YorkAges 18 years+ - NCT05239624RecruitingPhase 2
Enfortumab plus pembrolizumab for muscle-invasive bladder cancer
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
Miami, FloridaAges 18 years+ - NCT05290038Recruiting
Review study for adults with metastatic UC treated with specific drugs
This is a study that looks back at past medical records of adults with metastatic urinary tract cancer. It specifically includes people who received certain immunotherapy or antibody-drug treatments during set time periods, to help researchers understand outcomes and care patterns.
Province of Macerata, MacerataAges 18 years+ - NCT05296564RecruitingPhase 1/Phase 2
TCR cell therapy for NY-ESO-1 positive metastatic cancers
This study tests a customized immune-cell treatment made from your own T cells to attack cancers that have NY-ESO-1. It may help shrink tumors in people with metastatic or hard-to-treat cancer when other treatments have not worked.
JerusalemAges 18–70 - NCT05337189Recruiting
Urine DNA test study for possible bladder cancer
This trial looks at how a urine DNA test may help find bladder cancer (or clues that it might be present), especially in people with symptoms or higher risk. You may be asked to provide urine and also complete standard tests like imaging, a cystoscopy, or pathology checks.
Beijing, Beijing MunicipalityAges Any age - NCT05394337RecruitingPhase 1/Phase 2
Immunotherapy before bladder surgery for cisplatin-ineligible patients
This trial tests two immunotherapy drugs given before bladder/urinary tract cancer surgery. It aims to shrink the tumor and improve outcomes in people who cannot safely take cisplatin chemotherapy.
Houston, TexasAges 18 years+ - NCT05646485Recruiting
Bladder cancer screening for people at higher risk
This trial tests screening for bladder cancer in people who have higher risk due to age, smoking, and certain job exposures. It may help find bladder cancer earlier when treatment can be more effective.
Dallas, TexasAges 50 years+
Hear when a new Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for urothelial carcinoma?
- Yes. Clin2 currently lists 203 recruiting urothelial carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a urothelial carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a urothelial carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Urothelial Carcinoma Bladder
- Metastatic Urothelial Carcinoma
- Upper Tract Urothelial Carcinoma
- Advanced Urothelial Carcinoma
- Muscle Invasive Bladder Urothelial Carcinoma
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Non-Muscle Invasive Bladder Urothelial Carcinoma
- Upper Urinary Tract Urothelial Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.